Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors - Wikidata - wikimedia - TriplyDB

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

http://www.wikidata.org/entity/Q35967197

about

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex Contemporary Treatment of Metastatic Renal Cell Carcinoma Profile of nintedanib in the treatment of solid tumors: the evidence to date MET inhibitors in combination with other therapies in non-small cell lung cancer Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme Intertwined regulation of angiogenesis and immunity by myeloid cells Cabozantinib for progressive metastatic medullary thyroid cancer: a review Anti-angiogenesis and metastasis: a tumour and stromal cell alliance Mouse models for studying angiogenesis and lymphangiogenesis in cancer Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma Intraoperative intravital microscopy permits the study of human tumour vessels Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2 The Metastatic Potential and Chemoresistance of Human Pancreatic Cancer Stem Cells Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.In Vivo Visualization and Characterization of Epithelial-Mesenchymal Transition in Breast Tumors.Gene expression profile analysis of pancreatic cancer based on microarray data.A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study The amelioration of cartilage degeneration by photo-crosslinked GelHA hydrogel and crizotinib encapsulated chitosan microspheres.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.Cediranib for metastatic alveolar soft part sarcoma AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.Potential Role of Semaphorin 3A and Its Receptors in Regulating Aberrant Sympathetic Innervation in Peritoneal and Deep Infiltrating Endometriosis

P2860

Q24293027-224741CE-F8F4-4E6B-A2AD-36DF6A5D8054 Q26740594-E4C6E7C0-9A4D-4C80-8967-4D522C4DC2AB Q26775134-F8A6BC52-BFAD-40A4-9670-CDAEF7F96447 Q26823203-4DF7D99D-84E4-4C0B-B637-CF13E8D36BA4 Q26824557-C2E0D943-238B-49B7-9D80-EB36A5E73715 Q26830418-1B3DB134-6448-4AF1-95DD-B2EB45E870B5 Q26851709-1AA2E459-D8D9-4A80-A563-C7CD81809765 Q26862741-E59CD461-31E6-457C-A32E-0231CBC41955 Q27003898-C33AED9E-4A89-4796-8039-0866448FEB08 Q27021470-C2509566-EE3D-467C-97A1-AA87C235928B Q27332331-302E3BDE-CCD6-482C-8D7C-49F06F61BD01 Q27853074-018D664E-7785-48E3-9894-145DC6F11B69 Q28074834-4461242C-26DD-436C-A1D8-0DF93C738BEE Q28081193-D76C9071-03D5-4EAB-BFCA-A93860DFF59E Q28487568-23BAA9F3-3777-4342-BA5A-6F3C6AA41D81 Q28550040-DA9329C0-B404-47E9-BE50-0BE76D162C61 Q30278053-4DE6F640-6703-4D22-A23E-468A07C85602 Q30399006-34AE598F-F418-45A7-B971-8AE2117B6106 Q30759342-E04108BD-8BE2-4EDB-A006-815575D04618 Q31066570-C060AFCF-C273-411E-AEBC-50980FF188CC Q33424270-883A2F3C-13B8-4F41-8DBF-2783F5DACC08 Q33441170-E9F652D8-689E-4225-B2CB-9F2AC0628D7B Q33728287-26C3C22C-128A-425E-AD2B-42BB8A04D3F0 Q33770680-9A75C2C8-973A-4D3E-8FBE-EC5CE7E7877A Q33886974-C966EA20-C63F-4596-9793-85F70DA6F7C5 Q33888739-638FC5AC-7991-4A79-8DC9-17BCD36047EE Q34041747-3CF559C3-CB9B-4BBB-B44F-E91DA22165D2 Q34104074-970BB6BC-59D9-4E5F-912C-04BE89337A76 Q34495684-6209368E-E843-4B52-B0C0-09974E2B8775 Q34537725-559DAC31-AF2C-4FD8-B840-B7D411D66016 Q34651131-E1F5EF57-C2D9-4CD6-9ED2-89E1D658E4CC Q34665377-18D55565-D027-4B88-90D2-1D8837E40115 Q34774912-20F5919C-C06B-44D2-9BF2-8C0D9470E8EE Q34880943-714470B9-3032-44C2-A85F-695E99A2F148 Q34978329-0A57B400-51C2-4928-A717-EEAE04D947A1 Q35036800-87007AB3-CEA8-4175-B97C-BD976D62EB44 Q35051790-F6B8B4D4-DBB3-4483-8A55-08E905DB2452 Q35133904-8FB2478F-625B-47A0-8FED-C887E43B5D55 Q35670576-09D86C61-DC7A-4E60-9E61-5EDE8BA12AFD Q35882677-C4514788-3F97-4206-97C1-5CFEEF5FA452

P2860

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

http://www.wikidata.org/entity/Q35967197

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Suppression of tumor invasion ...... ncreatic neuroendocrine tumors

@ast

Suppression of tumor invasion ...... ncreatic neuroendocrine tumors

@en

type

label

Suppression of tumor invasion ...... ncreatic neuroendocrine tumors

@ast

Suppression of tumor invasion ...... ncreatic neuroendocrine tumors

@en

prefLabel

Suppression of tumor invasion ...... ncreatic neuroendocrine tumors

@ast

Suppression of tumor invasion ...... ncreatic neuroendocrine tumors

@en

P1433

Q35967197-473A054C-F6E3-4BE4-8546-B2DBEF33B293

P1476

Q35967197-FDC71EEF-1801-4084-AEE1-CE3A196C4DAC

P2093

Q35967197-03D8DD7D-A6A7-402D-96CA-9939C532190E

Q35967197-19BC7904-9215-46D2-ABEB-D61A3CA06B04

Q35967197-3217669B-8EC1-422F-B35B-EF2191C42564

Q35967197-4E0257DE-470F-4B92-92E4-D2E97F8535C9

Q35967197-4EF2E763-EAB7-46DF-A579-373E620E35DE

Q35967197-5E8AB0BD-BAE6-4B71-A53B-35B95AB78372

Q35967197-7E70AD6E-1F66-450D-84AF-2021893FA6CE

Q35967197-991A14D6-2E5E-4F08-87F9-29897669E89E

Q35967197-AC5009CF-B5D8-4B01-B57C-C8B81EAE490B

Q35967197-AE786099-28AB-4A97-92DF-3CD9696C6FFC

P2860

Q35967197-0315E872-6CF3-4BE0-860E-F3A59B21B030

Q35967197-077B3041-2D6F-44E3-B46A-69DD074D1954

Q35967197-0908CBA8-FCB0-4405-9EA6-DD05D9860DBE

Q35967197-0F3CCE28-CAD8-4760-AB1B-58F4E75D8617

Q35967197-11F5135E-61E1-4A0D-9AB7-F6688FB43889

Q35967197-1312E567-61D2-4AC5-811E-EAB58AC4EA1B

Q35967197-13B6124C-BCC0-4170-B2BD-BF4047F28B6A

Q35967197-1605DC43-C291-43B4-ADB8-D19F90324023

Q35967197-1C373261-6F9A-4D17-A612-4927CBA7693A

Q35967197-1D60E7EF-2212-4A95-855A-1F621DAD2DFC

P304

Q35967197-EAC3FA44-9E2C-47AB-85AB-0413C8464203

P31

Q35967197-792F39E4-0BFF-43C3-A1BA-27C6B499F8B5

P356

Q35967197-8A929D0B-773E-467C-A414-C32E9B4AE2A5

P433

Q35967197-77A654AC-DDA3-476E-BBBD-BFD146DE0860

P478

Q35967197-4B4D5AE2-5589-4C00-B800-50A5AFB1745F

P577

Q35967197-5312D762-B7DE-4015-B7CF-5005137FAFE1

P698

Q35967197-C9E31203-73E3-4B7F-9628-8544BC6D735E

P921

Q35967197-83C4E3BF-EA95-4942-A310-E5FEF4B6437D

P932

Q35967197-37446276-F0F0-4D87-BEF1-DCB28B14D9DE

P356

2159-8290.CD-11-0240

P1433

Cancer Discovery

P1476

Suppression of tumor invasion ...... ncreatic neuroendocrine tumors

@en

P2093

Barbara Sennino

http://www.w3.org/2001/XMLSchema#string

Casey W Williamson

http://www.w3.org/2001/XMLSchema#string

Dana T Aftab

http://www.w3.org/2001/XMLSchema#string

Donald M McDonald

http://www.w3.org/2001/XMLSchema#string

Harold A Chapman

http://www.w3.org/2001/XMLSchema#string

James G Christensen

http://www.w3.org/2001/XMLSchema#string

Ryan M Naylor

http://www.w3.org/2001/XMLSchema#string

Sebastien P Tabruyn

http://www.w3.org/2001/XMLSchema#string

Toshina Ishiguro-Oonuma

http://www.w3.org/2001/XMLSchema#string

Vikash Bhagwandin

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Epithelial-mesenchymal transitions in tumour progression

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

The snail superfamily of zinc-finger transcription factors

Targeting the c-Met signaling pathway in cancer

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

P304

270-287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-11-0240

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22585997

http://www.w3.org/2001/XMLSchema#string

P921

P932

3354652

http://www.w3.org/2001/XMLSchema#string